Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Raptiva (efalizumab), efalizumab
Raptiva · 5 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| efalizumab | DRUG | - |
| Raptiva (efalizumab) | DRUG | - |
Inclusion Criteria: * Signed informed consent * Plaque psoriasis covering \>=10% of total BSA * Plaque psoriasis diagnosed for at least 6 months * In the opinion of the investigator, a candidate for systemic therapy for psoriasis * 18-75 years old * Body weight \<=125 kg * For women of childbearing...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
Raptiva is a monoclonal antibody developed for the treatment of plaque psoriasis and psoriasis, a chronic inflammatory skin condition. It was studied in adults with moderate to severe plaque psoriasis, including patients who were candidates for systemic therapy. Raptiva is also known by its generic name, efalizumab.
Raptiva is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the clinical trial program evaluating efalizumab in plaque psoriasis, including Phase 1 and Phase 3 studies conducted in adult patients with moderate to severe forms of the disease.
Raptiva is an investigational monoclonal antibody that has been studied in clinical development, with a Phase 1 trial and multiple Phase 3 trials in plaque psoriasis. All four listed trials are completed, and no trials are currently active. The program enrolled a total of 1,136 participants across its studies.
Raptiva has been evaluated in completed trials including NCT00382512, a Phase 1 study of immune responses in moderate plaque psoriasis, and NCT00109317, a Phase 3 study in adults with moderate to severe plaque psoriasis. Additional completed Phase 3 trials include NCT00109252 and NCT00096603, which assessed Raptiva in previously enrolled psoriasis patients.
Yes, Raptiva is the brand name for efalizumab, a monoclonal antibody. The two names refer to the same drug candidate, so searches for either Raptiva or efalizumab point to the same development program in plaque psoriasis and psoriasis led by Roche Holding AG.
The Raptiva clinical program enrolled 1,136 participants across its completed trials. The largest study, NCT00109317, enrolled 686 adults with moderate to severe plaque psoriasis, while NCT00096603 enrolled 450 patients and NCT00382512 enrolled 60 participants. One Phase 3 trial, NCT00109252, listed zero enrollment.